secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001558370-25-003405
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Q4 net income $2.6M; Phase 2 AP-PA02 positive; $10M credit deal
----------------------------------------------------------------------

- Q4 net income $2.6M ($0.07 basic, -$0.23 diluted) vs net loss $19.8M YoY; includes $14.2M non-cash gain.
- Phase 2 Tailwind study of inhaled AP-PA02 in NCFB showed statistically significant reduction of P.a. CFUs; well-tolerated.
- Phase 1b/2a diSArm study of IV AP-SA02 for S. aureus bacteremia enrollment complete; topline data expected H1 2025.
- Entered $10M secured credit agreement with Innoviva subsidiary at 14% interest, maturing March 2026; existing loans also extended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/0001558370-25-003405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/armp-20250320x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer